Founders Financial Securities added new position in Bristol-Myers Squibb Co during the most recent quarter end. The investment management firm now holds 5,912 shares of Bristol-Myers Squibb Co which is valued at $353,124 , the company said in a statement filed on Jan 10, 2017 with the SEC.Bristol-Myers Squibb Co makes up approximately 0.14% of Founders Financial Securitiess portfolio.
Other Hedge Funds, Including , Carlton Hofferkamp Jenks Wealth Management boosted its stake in BMY in the latest quarter, The investment management firm added 1,800 additional shares and now holds a total of 7,900 shares of Bristol-Myers Squibb Co which is valued at $471,867. Bristol-Myers Squibb Co makes up approx 0.34% of Carlton Hofferkamp Jenks Wealth Managements portfolio.Integrated Wealth Management reduced its stake in BMY by selling 1,369 shares or 9.52% in the most recent quarter. The Hedge Fund company now holds 13,018 shares of BMY which is valued at $780,429. Bristol-Myers Squibb Co makes up approx 0.29% of Integrated Wealth Managements portfolio.Eqis Capital Management boosted its stake in BMY in the latest quarter, The investment management firm added 7,653 additional shares and now holds a total of 23,659 shares of Bristol-Myers Squibb Co which is valued at $1,422,616. Bristol-Myers Squibb Co makes up approx 0.09% of Eqis Capital Managements portfolio.First American Trust Fsb boosted its stake in BMY in the latest quarter, The investment management firm added 15,086 additional shares and now holds a total of 103,916 shares of Bristol-Myers Squibb Co which is valued at $6,177,806. Bristol-Myers Squibb Co makes up approx 1.90% of First American Trust Fsbs portfolio.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.
Bristol-Myers Squibb Co closed down -0.25 points or -0.44% at $56.55 with 99,77,917 shares getting traded on Thursday. Post opening the session at $56.5, the shares hit an intraday low of $56.015 and an intraday high of $56.78 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
On the companys financial health, Bristol-Myers Squibb Co reported $0.77 EPS for the quarter, beating the analyst consensus estimate by $ 0.12 according to the earnings call on Oct 27, 2016. Analyst had a consensus of $0.65. The company had revenue of $4922.00 million for the quarter, compared to analysts expectations of $4796.98 million. The companys revenue was up 21.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.39 EPS.
Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Bristol-Myers Squibb Co was Upgraded by Jefferies to Buy on Dec 19, 2016. Shares were Reiterated by Deutsche Bank on Oct 28, 2016 to Hold and Lowered the Price Target to $ 52 from a previous price target of $59 .
(c) 2017 2016 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers